Open AccessA New Heterocyclic 1H-perimidine synthesized 2-(2,3-dihydro-1H-périmidin-2yl-)-6-methoxyphenol: Evaluation of Acute Toxicity in Wistar Rat
Author(s) -
Tuo Nanou Tiéba,
Pacôme Kouadio N’Go,
Ballo Daouda,
Kangah Niameke Jean Baptiste,
Kodjo Charles Guillaume,
Yapo Ossey Bernard,
Nahossé Ziao
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i24b31441
Subject(s) - acute toxicity , toxicity , no observed adverse effect level , pharmacology , body weight , chemistry , toxicology , dimethyl sulfoxide , food consumption , medicine , biology , organic chemistry , agricultural economics , economics
Background and Aim: The 1H-perimidne, as novel source carbene ligand, is well known for its anti-fungal, anti-microbial or anti-tumor activities. Here, we aimed to study the acute toxicity in Wistar rat of 2-(2,3-dihydro-1H-perimidin-2-yl)-6-methoxyphenol, a new heterocyclic 1H- perimidine synthetized in our laboratory.
Materials and Methods: Five groups of males Wistar rats were intraperitoneally injected with 7 mg/kg, 40 mg/kg, 90 mg/kg, 130 mg/kg and 150 mg/kg dissolved in dimethyl sulfoxide (DMSO), and followed during 14 days. We noted any clinical signs of acute toxicity as body weight loss, salivation, tremor, convulsion among others, as well as food consumption and water intake level.
Results: The DL50 of the new 2-(2,3-dihydro-1H-perimidin-2-yl)-6-methoxyphenol was estimated to 65 mg/kg. The No Observed Adverse Effect Level (NOAEL) dose was 7 mg/kg because it did not caused mortality, clinical signs of acute toxicity, and not affected feed and water intake behavior. However, significant abnormalities as inflammation and necrosis were observed at doses-effects dependent in liver, when compared to NOAEL dose and vehicle.
Conclusion: The new heterocyclic 2-(2,3-dihydro-1H-perimidin-2-yl)-6-methoxyphenol is considered as high toxicity grade product. From NOAEL dose, subsequent biological, toxicological, pharmacological and neurobehavioral studies are needed before using for clinical trials.